| |
| |
|
| Insider
Information: |
Almon Einat Brill |
| Relationship: |
SVP, Product Development |
| City: |
Carmiel, Israel |
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
185,000 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$48,951 |
|
|
| Total
Shares |
185,000 |
|
|
| Total
Value |
$48,951 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Protalix Biotherapeutics |
PLX |
SVP, Product Development |
2009-05-18 |
0 |
2012-07-16 |
185,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PLX |
Protalix Biotherapeutics |
SVP, Product Development |
• – – |
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
185,000 |
185,000 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-10-06 |
4 |
OE |
$0.97 |
$68,040 |
I/I |
70,000 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-10-06 |
4 |
AS |
$9.29 |
$139,350 |
I/I |
(15,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-10-05 |
4 |
AS |
$9.08 |
$181,600 |
I/I |
(20,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-10-04 |
4 |
AS |
$9.02 |
$315,700 |
I/I |
(35,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-09-07 |
4 |
AS |
$8.16 |
$183,600 |
I/I |
(22,500) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-09-07 |
4 |
OE |
$0.40 |
$45,884 |
I/I |
50,000 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2010-09-03 |
4 |
AS |
$8.00 |
$220,000 |
I/I |
(27,500) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-10-19 |
4 |
D |
$9.48 |
$37,484 |
I/I |
(3,954) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-10-19 |
4 |
OE |
$0.40 |
$37,488 |
I/I |
93,954 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-10-19 |
4 |
AS |
$9.43 |
$361,358 |
I/I |
(38,320) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-10-16 |
4 |
AS |
$9.39 |
$222,355 |
I/I |
(23,680) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-10-15 |
4 |
AS |
$9.39 |
$262,920 |
I/I |
(28,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-07-07 |
4 |
AS |
$4.95 |
$54,450 |
I/I |
(11,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-07-07 |
4 |
OE |
$0.40 |
$23,869 |
I/I |
59,822 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-07-07 |
4 |
D |
$4.95 |
$23,869 |
I/I |
(4,822) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-07-06 |
4 |
AS |
$5.13 |
$225,720 |
I/I |
(44,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-05-18 |
4 |
S |
$4.00 |
$160,000 |
I/I |
(40,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-05-18 |
4 |
D |
$3.79 |
$17,840 |
I/I |
(4,707) |
40,000 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2009-05-18 |
4 |
OE |
$0.40 |
$17,838 |
I/I |
44,707 |
44,707 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2008-05-12 |
4 |
S |
$2.75 |
$113,924 |
I/I |
(41,427) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2008-05-11 |
4 |
OE |
$0.40 |
$19,251 |
I/I |
48,370 |
48,370 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Product Development |
• – – |
2008-05-11 |
4 |
D |
$2.78 |
$19,302 |
I/I |
(6,943) |
41,427 |
0 |
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
